Treatment Satisfaction With Ra-223 in Japan

Inclusion Criteria: * Age ≥20 years old (age of maturity in Japan) * Male, diagnosed with CRPC * With ≥2 bone metastases and no visceral metastasis based on the most recent imaging procedure * Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 0-1, not in end-stage palliative care * Designated by examining physician to undergo Ra-223 treatment either in the 1st, 2nd, or 3rd line of CRPC therapy * Has provided written, informed consent (in Japanese) * Has ≥6 months life expectancy Exclusion Criteria: * Participation in an investigational program with interventions outside of routine clinical practice * Currently receiving any chemotherapy for CRPC or any new hormone therapy (enzalutamide, abiraterone acetate) at enrolment * Where any of the below conditions apply: * Started or switched to new androgen deprivation therapy (ADT) (e.g., LHRH agonists and antagonists, anti-androgens, estrogens,) within 4 weeks prior to enrolment or planning to start new treatment prior to 1st Ra-223 injection * Treatment with anticancer-chemotherapy within previous 4 weeks, or planned before the 1st Ra-223 injection, or failure to recover from adverse events (AEs) (CTCAE Grade \>2) due to anticancer chemotherapy administered more than 4 weeks prior * Systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within the previous 24 weeks * Previous hemi-body external radiotherapy * Imminent or established spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI) * Presence of other maligancy at enrolment * Otherwise deemed incapable of participating by examining physician